FDA clears Bards endoscopic biliary stent:
This article was originally published in Clinica
Executive Summary
CR Bard has received US FDA 510(k) clearance to market its Memotherm endoscopic biliary stent for treating malignant biliary obstructions. The product offers a minimally invasive option for managing patients whose biliary tracts become obstructed due to tumour growth, a condition affecting more than 30,000 people in the US every year, says the Murray Hill, New Jersey company.